Yeo A, Li L, Warren L, Aponte J, Fraser D, King K, Johansson K, Barnes A, Macphee C, Davies R, Chissoe S, Tarka E, O'Donoghue ML, White HD, Wallentin L, Waterworth D (2017) <br />Pharmacogenetic meta-analysis of baseline risk factors, pharmacodynamic, efficacy and tolerability endpoints from two large global cardiovascular outcomes trials for darapladib<br /><i>PLoS ONE</i> <b>12</b>: e0182115<br /><br />